Kopran Q3 EBITDA Drops 10% YoY to ₹178M

Kopran reported Q3 EBITDA of ₹178 million, down from ₹198 million year-over-year, with EBITDA margin declining to 9.14% from 11.93% in the same period last year.

Kopran Faces GST Authority Search at Facilities

Maharashtra GST authorities initiated search operations at Kopran Limited's Mumbai office and Khopoli facility on January 21, 2026, under Section 67 of state GST Act. Company cooperating fully.

Kopran Board Meeting Set for January 22, 2026

Kopran Limited has scheduled a board meeting on January 22, 2026, to consider and approve unaudited standalone and consolidated financial results for Q3FY26 ended December 31, 2025.

Kopran Limited Gets CRISIL Rating Reaffirmation

CRISIL reaffirms credit ratings for Kopran Limited and subsidiary with BBB+/watch developing for long-term and A2/watch developing for short-term facilities till March 31, 2026.

Kopran Limited Reports Mixed Financial Performance in Q2 FY2025

Kopran Limited announced its quarterly results for the quarter ended September 30, 2025. On a consolidated basis, the company reported revenue from operations of Rs 790.93 lakhs compared to Rs 15,156.29 lakhs in the same quarter last year. The company posted a net loss of Rs 992.32 lakhs for the quarter versus a profit of Rs 738.41 lakhs in the corresponding period of the previous year. For the half-year period, consolidated revenue stood at Rs 25,312.55 lakhs compared to Rs 29,099.84 lakhs in the previous year. The company's standalone revenue for the quarter was Rs 4,238.93 lakhs against Rs 7,352.96 lakhs in the same quarter last year. The Board of Directors approved these unaudited financial results at their meeting held on November 12, 2025. The company operates primarily in the pharmaceuticals business through its group entities.